Dysregulation of genes coding for proteins involved in metabolic processes in mucopolysaccharidoses, evidenced by a transcriptomic approach.
Mucopolysaccharidoses
Regulation of metabolic processes
Transcriptomics
Journal
Metabolic brain disease
ISSN: 1573-7365
Titre abrégé: Metab Brain Dis
Pays: United States
ID NLM: 8610370
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
received:
11
04
2023
accepted:
07
05
2023
medline:
17
7
2023
pubmed:
17
5
2023
entrez:
17
5
2023
Statut:
ppublish
Résumé
Mucopolysaccharidoses (MPS) are a group of lysosomal storage diseases (LSD) caused by mutations in genes coding for enzymes responsible for degradation of glycosaminoglycans (GAGs). Most types of these severe disorders are characterized by neuronopathic phenotypes. Although lysosomal accumulation of GAGs is the primary metabolic defect in MPS, secondary alterations in biochemical processes are considerable and influence the course of the disease. Early hypothesis suggested that these secondary changes might be due to lysosomal storage-mediated impairment of activities of other enzymes, and subsequent accumulation of various compounds in cells. However, recent studies indicated that expression of hundreds of genes is changed in MPS cells. Therefore, we asked whether metabolic effects observed in MPS are caused primarily by GAG-mediated inhibition of specific biochemical reactions or appear as results of dysregulation of expression of genes coding for proteins involved in metabolic processes. Transcriptomic analyses of 11 types of MPS (using RNA isolated from patient-derived fibroblasts), performed in this study, showed that a battery of the above mentioned genes is dysregulated in MPS cells. Some biochemical pathways might be especially affected by changes in expression of many genes, including GAG metabolism and sphingolipid metabolism which is especially interesting as secondary accumulation of various sphingolipids is one of the best known additional (while significantly enhancing neuropathological effects) metabolic defects in MPS. We conclude that severe metabolic disturbances, observed in MPS cells, can partially arise from changes in the expression of many genes coding for proteins involved in metabolic processes.
Identifiants
pubmed: 37195412
doi: 10.1007/s11011-023-01231-5
pii: 10.1007/s11011-023-01231-5
pmc: PMC10349023
doi:
Substances chimiques
Glycosaminoglycans
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2133-2144Informations de copyright
© 2023. The Author(s).
Références
Paediatr Respir Rev. 2011 Jun;12(2):133-8
pubmed: 21458742
J Hum Genet. 2019 Feb;64(2):127-137
pubmed: 30451936
Int J Mol Sci. 2020 Feb 11;21(4):
pubmed: 32054071
Int J Mol Sci. 2023 Feb 15;24(4):
pubmed: 36835321
Cell Biol Int. 2021 Mar;45(3):498-506
pubmed: 31855304
Metab Brain Dis. 2017 Oct;32(5):1403-1415
pubmed: 28382573
Mol Genet Metab. 2018 Sep;125(1-2):4-17
pubmed: 30057281
J Transl Med. 2018 Sep 4;16(1):248
pubmed: 30180851
J Appl Genet. 2022 Sep;63(3):475-495
pubmed: 35562626
BMC Med Genomics. 2013 Oct 02;6:37
pubmed: 24083598
Indian J Ophthalmol. 2022 Jul;70(7):2249-2261
pubmed: 35791104
Int J Mol Sci. 2020 Feb 10;21(3):
pubmed: 32050523
Mol Genet Metab. 2016 May;118(1):41-54
pubmed: 27053151
Front Neurosci. 2019 Feb 28;13:164
pubmed: 30872998
Genes (Basel). 2023 Jan 20;14(2):
pubmed: 36833198
Mol Genet Metab. 2020 Feb;129(2):111-116
pubmed: 31494022
Mol Genet Metab. 2019 Sep - Oct;128(1-2):75-83
pubmed: 31097363
Bone. 2019 Nov;128:115042
pubmed: 31442675
PLoS One. 2012;7(3):e32419
pubmed: 22403656
Biomedicines. 2023 Mar 07;11(3):
pubmed: 36979788
Development. 2018 Oct 1;145(19):
pubmed: 30275240
J Clin Med. 2020 Jan 27;9(2):
pubmed: 32012694
Intractable Rare Dis Res. 2020 Feb;9(1):1-9
pubmed: 32201668
Int J Mol Sci. 2020 Apr 07;21(7):
pubmed: 32272755
Biochem J. 2017 Feb 15;474(4):589-596
pubmed: 27993971
Clin Exp Med. 2023 Sep;23(5):1375-1391
pubmed: 36098834
Mov Disord. 2020 Mar;35(3):508-513
pubmed: 31930747
Diagnostics (Basel). 2020 Mar 22;10(3):
pubmed: 32235807
Int J Mol Sci. 2022 Dec 28;24(1):
pubmed: 36613919
Clin Orthop Relat Res. 1976 Jan-Feb;(114):116-33
pubmed: 131015
Pharmaceutics. 2023 Feb 20;15(2):
pubmed: 36840025
Pediatr Neonatol. 2023 Feb;64 Suppl 1:S10-S17
pubmed: 36464587
Expert Opin Ther Targets. 2017 Feb;21(2):201-213
pubmed: 27978767
Int J Mol Sci. 2020 Apr 04;21(7):
pubmed: 32260444
Int J Mol Sci. 2020 Apr 30;21(9):
pubmed: 32366041
Proc Natl Acad Sci U S A. 1976 Feb;73(2):630-7
pubmed: 813230
Hum Mol Genet. 2018 Oct 15;27(20):3612-3626
pubmed: 30052969
Genes (Basel). 2022 Mar 26;13(4):
pubmed: 35456399
Int J Mol Sci. 2017 May 17;18(5):
pubmed: 28513549
Eur J Cell Biol. 2022 Jun-Aug;101(3):151232
pubmed: 35537249
J Biol Chem. 2009 Aug 14;284(33):22029-22040
pubmed: 19502598
Cell Biol Int. 2021 Mar;45(3):549-557
pubmed: 32125037
Front Immunol. 2018 Oct 09;9:2316
pubmed: 30356731
Acta Paediatr. 2009 Apr;98(4):743-9
pubmed: 19046346